These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 2477164

  • 1. Modulation of the antineoplastic efficacy of mitomycin C by dicoumarol in vivo.
    Rockwell S, Keyes SR, Sartorelli AC.
    Cancer Chemother Pharmacol; 1989; 24(6):349-53. PubMed ID: 2477164
    [Abstract] [Full Text] [Related]

  • 2. Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells.
    Keyes SR, Rockwell S, Sartorelli AC.
    Cancer Res; 1989 Jun 15; 49(12):3310-3. PubMed ID: 2470504
    [Abstract] [Full Text] [Related]

  • 3. Modulation of the cytotoxicity of mitomycin C to EMT6 mouse mammary tumor cells by dicoumarol in vitro.
    Rockwell S, Keyes SR, Sartorelli AC.
    Cancer Res; 1988 Oct 01; 48(19):5471-4. PubMed ID: 2458178
    [Abstract] [Full Text] [Related]

  • 4. Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro.
    Keyes SR, Rockwell S, Sartorelli AC.
    Cancer Res; 1985 Jan 01; 45(1):213-6. PubMed ID: 2578093
    [Abstract] [Full Text] [Related]

  • 5. Adducts of mitomycin C and DNA in EMT6 mouse mammary tumor cells: effects of hypoxia and dicumarol on adduct patterns.
    Bizanek R, Chowdary D, Arai H, Kasai M, Hughes CS, Sartorelli AC, Rockwell S, Tomasz M.
    Cancer Res; 1993 Nov 01; 53(21):5127-34. PubMed ID: 7693331
    [Abstract] [Full Text] [Related]

  • 6. Bioreductive metabolism of mitomycin C in EMT6 mouse mammary tumor cells: cytotoxic and non-cytotoxic pathways, leading to different types of DNA adducts. The effect of dicumarol.
    Palom Y, Belcourt MF, Tang LQ, Mehta SS, Sartorelli AC, Pritsos CA, Pritsos KL, Rockwell S, Tomasz M.
    Biochem Pharmacol; 2001 Jun 15; 61(12):1517-29. PubMed ID: 11377381
    [Abstract] [Full Text] [Related]

  • 7. Modulation of the cytotoxicity of porfiromycin by dicoumarol in vitro and in vivo.
    Rockwell S, Keyes SR, Sartorelli AC.
    Anticancer Res; 1989 Jun 15; 9(4):817-20. PubMed ID: 2479329
    [Abstract] [Full Text] [Related]

  • 8. The role of mitomycin antibiotics in the chemotherapy of solid tumors.
    Sartorelli AC.
    Biochem Pharmacol; 1986 Jan 01; 35(1):67-9. PubMed ID: 2416320
    [No Abstract] [Full Text] [Related]

  • 9. Increased sensitivity of quinone resistant cells to mitomycin C.
    Begleiter A, Robotham E, Lacey G, Leith MK.
    Cancer Lett; 1989 Jun 01; 45(3):173-6. PubMed ID: 2471583
    [Abstract] [Full Text] [Related]

  • 10. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1.
    Keyes SR, Fracasso PM, Heimbrook DC, Rockwell S, Sligar SG, Sartorelli AC.
    Cancer Res; 1984 Dec 01; 44(12 Pt 1):5638-43. PubMed ID: 6437671
    [Abstract] [Full Text] [Related]

  • 11. Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H: (quinone-acceptor)oxidoreductase.
    Schlager JJ, Powis G.
    Cancer Chemother Pharmacol; 1988 Dec 01; 22(2):126-30. PubMed ID: 3136941
    [Abstract] [Full Text] [Related]

  • 12. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells.
    Siegel D, Gibson NW, Preusch PC, Ross D.
    Cancer Res; 1990 Dec 01; 50(23):7483-9. PubMed ID: 1701346
    [Abstract] [Full Text] [Related]

  • 13. Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C.
    Keyes SR, Heimbrook DC, Fracasso PM, Rockwell S, Sligar SG, Sartorelli AC.
    Adv Enzyme Regul; 1985 Dec 01; 23():291-307. PubMed ID: 3934922
    [Abstract] [Full Text] [Related]

  • 14. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
    Keyes SR, Rockwell S, Sartorelli AC.
    Cancer Res; 1985 Aug 01; 45(8):3642-5. PubMed ID: 3926306
    [Abstract] [Full Text] [Related]

  • 15. Effects of the mode of administration of mitomycin on tumor and marrow response and on the therapeutic ratio.
    Rockwell S, Nierenburg M, Irvin CG.
    Cancer Treat Rep; 1987 Oct 01; 71(10):927-34. PubMed ID: 3652056
    [Abstract] [Full Text] [Related]

  • 16. Effects of glutathione and ethylxanthate on mitomycin C activation by isolated rat hepatic or EMT6 mouse mammary tumor nuclei.
    Kennedy KA, Mimnaugh EG, Trush MA, Sinha BK.
    Cancer Res; 1985 Sep 01; 45(9):4071-6. PubMed ID: 2411396
    [Abstract] [Full Text] [Related]

  • 17. Cytotoxicity of BMS-181174. Effects of hypoxia, dicoumarol, and repair deficits.
    Rockwell S, Kemple B, Kelley M.
    Biochem Pharmacol; 1995 Oct 12; 50(8):1239-43. PubMed ID: 7488240
    [Abstract] [Full Text] [Related]

  • 18. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
    Fracasso PM, Sartorelli AC.
    Cancer Res; 1986 Aug 12; 46(8):3939-44. PubMed ID: 3089583
    [Abstract] [Full Text] [Related]

  • 19. Interactions of BMS-181174 and radiation: studies with EMT6 cells in vitro and in solid tumors.
    Rockwell S, Kelley M.
    Radiother Oncol; 1996 Apr 12; 39(1):65-71. PubMed ID: 8735495
    [Abstract] [Full Text] [Related]

  • 20. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics.
    Pritsos CA, Sartorelli AC.
    Cancer Res; 1986 Jul 12; 46(7):3528-32. PubMed ID: 3011250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.